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Since the introduction of a two-dose MMR vaccina-
tion regime the incidence of mumps virus infections 
has substantially declined. However, mumps out-
breaks have recently been reported from several coun-
tries. Here we report an ongoing mumps outbreak in 
Germany. Between 1 July and 31 October, 115 infec-
tions have been laboratory-confirmed. Reported com-
plications include one case of meningitis and 21 cases 
of orchitis, suggesting a high rate of complications. 
We suggest a vaccination campaign for young adults 
in northern Bavaria to limit severe mumps infections.
Introduction 
Mumps virus infections may have a variable clinical 
outcome. Most commonly they lead to fever and paro-
titis. However, up to 30 per cent of male adolescent 
mumps cases develop orchitis. The German Standing 
Committee on Vaccination (Ständige Impfkommission, 
STIKO) recommends that children be vaccinated with 
two doses of MMR measles-mumps-rubella (MMR) 
or measles-mumps-rubella-varicella (MMRV) vaccine 
within their first two years of life (between 11 and 14 
months and between 15 and 23 months) [1]. Mumps is 
not a notifiable disease in Germany, therefore informa-
tion about mumps cases or outbreaks is scant. In other 
European countries, the introduction of a two-dose 
MMR vaccination regime resulted in a strong decline of 
the number of mumps virus infections [2-4]. However, 
resurgent outbreaks of mumps were recently reported 
from several European countries [2-11], the United 
States (US) and Canada [12-14]. Many of the outbreaks 
were seen in highly vaccinated populations, calling 
mumps virus vaccine efficiency into question [2-4, 
6-9]. Here we report on an ongoing mumps outbreak 
in Germany. 
Methods
The Synlab Medical Care Service Centre, Weiden, 
Bavaria, analyses laboratory samples from about 40 
hospitals and more than 2,000 physicians serving out-
patients predominantly from northern Bavaria [15]. In 
this study, results of serological mumps tests were 
evaluated. Data collected between January 2009 and 
October 2010 were examined. In total 1,248 serum 
samples were examined for IgM antibodies and 4,824 
samples for IgG antibodies. More than 99% of these 
samples were derived from Bavarian patients.
Mumps antibody testing of patient sera was per-
formed by using Enzygnost ELISA (anti-parotitis-virus/
IgM and anti-parotitis-virus/IgG, Siemens Healthcare 
Diagnostics Products, Marburg, Germany). Results of 
IgM ELISA were given as negative, borderline (equivo-
cal), and positive. Results of IgG ELISA were given 
as negative (<230 U/ml), borderline (equivocal) (230 
– 500 U/ml), and positive (>500 U/ml). In the present 
analysis acute mumps infection was assumed when 
patients were IgM antibody positive or when patients 
either showed a borderline IgM antibody test result in 
combination with typical symptoms or had detectable 
mumps virus ribonucleic acid (RNA). 
The German Reference Centre for measles, mumps and 
rubella virus at the Robert Koch Institut performed PCR 
analyses from either throat swabs and/or urine sam-
ples. The primers MuNP1 (5‘- AGTGTACTAATCCAGGCTTG 
-3‘) and C (5‘- ACCCACCATTGCATAGTATC -3‘) were used 
to carry out complimentary deoxyribonucleic acid 
(cDNA) synthesis (50°C, 30 min; 95°C, 15 min) and the 
subsequent first round of a nested PCR at 30x (94°C, 
30 sec; 52°C, 30 sec, 72°C, 1 min) plus 10 min 72°C. 
MuNP3 (5‘- GTATGACAGCGTACGACCAAC -3‘) and MuNP4 
5‘- GATAGCAACCCCTGCCGTCT -3‘ for the second round 
95°C, 5 min, 30 x (94°C, 30 sec; 52°C, 30 sec, 72°C, 
1 min). Genotyping of detected mumps virus was per-
formed as recommended in the Proposal for genetic 
characterisation of wild-type mumps strains [16]. 
Clinical data from mumps patients with orchitis were 
recorded at the Department of Urology at the St. Josef 
Medical Centre in Regensburg. The department of urol-
ogy is a facility of the University of Regensburg. 
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Results
In the pre-outbreak period from January 2009 to June 
2010 the number of patients infected with mumps 
virus was low (median per month N = 1 (range 0 – 
3)). However, this number has dramatically increased 
since the outbreak started. In July 2010 six patients 
tested positive for mumps IgM antibodies. In August 
18 patients tested positive, in September 22 patients 
and in October 32 patients, respectively. Additionally, 
in August 2010 eleven patients exhibiting mumps 
infection symptoms had borderline IgM test results. In 
September this number was eight and in October the 
number was 13.
Furthermore, positive PCR results were obtained from 
seven patients. Only two of the patients showed IgM 
antibodies while all PCR-positive patients exhibited 
IgG antibodies (median 14,000 U/ml). Genetic charac-
terisation of mumps virus detected in the clinical mate-
rial of seven cases revealed presence of genotype G. 
Figure
Regional localisation of mumps virus infections in Bavaria, Germany, August-October 2010a 
a The map shows the boundaries of the German federal state of Bavaria and boundaries of the Bavarian districts. Most cases were observed in 
Regensburg (southern Oberpfalz). Number of mumps cases per location is represented by the peaks of blue bars.
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In total 115 mumps infections were confirmed posi-
tive at the Weiden Synlab laboratory and at the Robert 
Koch Institute between 1 July and 31 October 2010. 
The median age was 24.5 years (mean 26.8 years, 
range 14–62 years). However, information on the vac-
cination status was available from only seven mumps 
patients. One of them was unvaccinated, one patient 
had received one dose of MMR and five patients had 
been vaccinated twice.
As illustrated in the Figure the majority of the infec-
tions occurred in the city of Regensburg (about 135,000 
inhabitants) or in the surrounding area. This finding 
was most prominent in August while in September and 
October an increasing number of cases were noted in 
the region located northwest of Regensburg. 
In August, one patient was diagnosed with mumps 
meningitis and a second case was suspected in 
November. In total 21 patients were treated at the St. 
Josef Hospital in Regensburg (median age 26 years) 
between July and October 2010, resulting in a total of 
76 days of hospitalisation (Table).  
Discussion
We give a preliminary description of an ongoing out-
break of mumps virus infection in northern Bavaria. 
Similarly to previous outbreaks in Austria, Luxembourg, 
Ireland and the Netherlands, the present outbreak 
affects mainly young adult patients [4, 5, 9,11]. 
We suppose that the actual number of affected patients 
is by far higher than 115 cases since certainly not every 
clinical case was confirmed in our laboratory. 
Furthermore, the present case definition in Germany 
uses positive IgM antibody and/or positive PCR results 
[17]. Many patients with clinical symptoms displayed 
high IgG antibody titres probably due to prior immuni-
sation or infection. As known from other viral diseases 
a viral re-infection is not necessarily accompanied by a 
rise in IgM antibodies but rather by an increase of IgG 
antibodies. Accordingly, during the outbreak months of 
July, August, September and October 2010, the median 
IgG titres were markedly higher than those observed 
in the previous months (January 2009–June 2010; 
data not shown). This supports the hypothesis that 
many mumps (re-)infections were accompanied by an 
increase of IgG antibody titre and not by the formation 
of IgM antibodies. This may have resulted in an under-
estimation in the number of mumps cases. Absence 
of mumps virus-specific IgM antibodies in the major-
ity of the clinical cases, as determined in the current 
outbreak in Germany, is concordant with the laboratory 
data reported by the Centers for Disease Control and 
Prevention from an outbreak observed in a highly vac-
cinated population in the US [12].
Table 
Clinical features of patients suffering from mumps orchitis, University Hospital of Regensburg, Germany July – October 
2010
Date of diagnosis Age (years) Mumps-IgG [U/ml] Mumps-IgM Symptoms
Hospital stay
[days]
16.07.2010 22 N.d. N.d. Fevera, testical swelling 6
22.07.2010 27 9,000 Positive Subfebrilityb, testical swelling, otitis 9
30.07.2010 24 N.d. N.d. Buccal and testical swelling 0
01.08.2010 25 22,000 Borderline Subfebrility, buccal, cervical and testical swelling 5
08.08.2010 26 670 Borderline Subfebrility, testical swelling 4
15.08.2010 22 24,000 N.d. Subfebrility, buccal and testical swelling 8
18.08.2010 22 15,000 Positive Fever, testical and epididymical swelling 6
17.08.2010 18 N.d. N.d. Fever, testical swelling 4
23.08.2010 37 N.d. N.d. Fever, buccal, testical and epididymical swelling 8
26.08.2010 33 N.d. N.d. Buccal and testical swelling 6
06.09.2010 18 N.d. N.d. Fever, testical swelling 4
06.09.2010 29 3,800 Positive Subfebrility, testical swelling 6
06.09.2010 44 8,000 Negative Testical swelling 0
16.09.2010 48 N.d. N.d. Fever, buccal, testical and epididymical swelling 6
22.09.2010 27 2,200 Positive Buccal and testical swelling 0
26.09.2010 24 15,000 Positive Fever, buccal, testical and epididymical swelling 4
23.09.2010 20 980 Positive Buccal, testical and epididymical swelling 0
26.09.2010 26 N.d. N.d. Subfebrility, buccal and testical swelling 0
27.09.2010 30 N.d. N.d. Testical swelling 0
03.10.2010 19 4,200 Positive Subfebrility, buccal, testical swelling 0
07.10.2010 30 N.d. N.d. Buccal, testical and epididymical swelling 0
N.d.: Not determined. 
a Body temperature > 38.5°C.
b Body temperature 37.5°C – 38.5°C.
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In contrast to Germany, mumps is a notifiable disease 
in Ireland and the Netherlands, where the collection of 
epidemiological data from many patients has been pos-
sible. In these populations the majority of the patients 
had been vaccinated and at least in the Dutch group 
most patients had been vaccinated twice [9]. Although 
we could get only limited information about vaccination 
status our data support the finding that most patients 
had been vaccinated completely indicating that com-
plete vaccination does not prevent mumps infection in 
an outbreak situation with absolute certainty. 
The current outbreak in Bavaria was caused by mumps 
virus genotype G. Previous analyses have revealed 
that this genotype was associated with several mumps 
outbreaks in Europe and the US [2,5,18,19]. The pos-
sible emergence of a mutant strain of mumps virus has 
been reported under the selective pressure of immuni-
sation with limited or no cross-protection induced by 
the vaccine strain [20]. A recent analysis indicated that 
individuals possessing low levels of neutralising anti-
bodies may be at risk for breakthrough infections [21]. 
These findings underline the importance of investigat-
ing whether the current situation in Germany is due to 
a high degree of susceptible individuals or to a break-
through of a currently circulating wildtype mumps 
virus. 
In the present outbreak, predominantly young male 
patients have been affected. Complications as mumps 
orchitis have resulted in the hospitalisation of at least 
13 young adult males. 
The outbreak started in the city of Regensburg (about 
135,000 inhabitants) and its surrounding area. In 
September and October an increasing number of 
cases was noted in the region located northwest of 
Regensburg. Due to very recent observations this trend 
also continued in November (data not shown) and it 
seems probable that the outbreak will soon reach the 
city of Nuremberg (about 500,000 inhabitants) and sur-
roundings with 1.2 million inhabitants.
Measures taken by public health service in Luxembourg 
were recently proven to help confining a mumps out-
break among the military staff [5]. Furthermore a mass-
vaccination successfully stopped a mumps outbreak in 
Austria [11]. Therefore it appears highly beneficial to 
initiate a vaccination campaign in northern Bavaria.
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